high-activity natural killer cell therapy
/ HANK Bioengineering
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 12, 2019
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
(clinicaltrials.gov)
- P1/2; N=20; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Jul 2019
Trial completion • Trial completion date
September 12, 2019
Combination of Rituximab and NK Immunotherapy for B Lymphoma
(clinicaltrials.gov)
- P1/2; N=30; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed
Trial completion
September 12, 2019
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
(clinicaltrials.gov)
- P1/2; N=20; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Jun 2019
Trial completion • Trial completion date
September 12, 2019
High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
(clinicaltrials.gov)
- P1/2; N=20; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Sep 2019
Trial completion • Trial completion date
September 12, 2019
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
(clinicaltrials.gov)
- P1/2; N=20; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Sep 2019
Trial completion • Trial completion date
September 12, 2019
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2; N=20; Completed; Sponsor: Fuda Cancer Hospital, Guangzhou; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Sep 2019
Trial completion • Trial completion date
1 to 6
Of
6
Go to page
1